EUR-1025
EUR-1025, Eurand’s once-a-day formulation of Ondansetron provides a more consistent and sustained release of drug, thereby extending time of drug action, an improvement identified by physicians as beneficial in this drug class.
| Collaboration Partner | Eurand |
| Development Status | Phase III |
| Therapeutic Category | Emesis |
| Target Indication(s) | Nausea and Vomiting |
| Eurand Technology Platform(s) | Diffucaps® - Controlled-release technology for poorly soluble drugs |
About EUR-1025
EUR-1025 is an oral 5-HT3 anti-emetic for the prevention of nausea and vomiting postoperatively or in patients undergoing chemotherapy or radiation treatment.
Eurand has ongoing discussions with the FDA regarding future development programs for this product.
Competitive Advantage
This novel, long-acting product is potentially the first ER Ondansetron product in this segment. This product is being developed using our Diffucaps® technology.
EUR-1025 has achieved positive results in pivotal PK studies—single and repeated oral administrations of EUR-1025 24 mg resulted in similar rate and extent of exposure as Zofran® 8 mg dosed TID.
Eurand is seeking a partner to co-develop and commercialize this product in the U.S. and other countries worldwide.